FDA 483 - WuXi Biologics Ireland Limited - December 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
WuXi Biologics Ireland Limited, a drug substance manufacturer in Dundalk, Ireland, was cited for deficiencies across its manufacturing and laboratory operations. Observations included high defect rates in manufacturing equipment, inadequate laboratory controls leading to high invalid assay rates, poor documentation practices, and inappropriate Out of Specification (OOS) investigation procedures. These issues indicate a need for improved quality system oversight and corrective actions.
ID · 46218d3f-8612-49e7-9718-ada2e1733c29